Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News
Nature Biotechnology 25, 1379–1381 (1 December 2007) | doi:10.1038/nbt1207-1379
Hepatitis C: staying the course
Abstract
2007 was a good year for hepatitis C—for the virus, that is. Companies, including seven biotechs, abandoned or suspended at least eight antiviral drugs in clinical development over the course of the year.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
